Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its SureSeq ™ portfolio with a complete library preparation solution for hybridization-based target capture in NGS, making ...
Oxford Gene Technology (OGT), A Sysmex Group Company, announces the addition of accurate detection capabilities for translocations and difficult-to-sequence partial tandem duplications (PTDs) in its ...
Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs Oxford, UK – 10 th November 2025. Today, OGT announced the launch of a new next-generation ...
Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq ™ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low frequency ...
The partnership between OGT and QIAGEN Digital Insights (QDI), expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq™ ...
Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback